Innovation Pharmaceuticals Inc (IPIX)

[frenchbroad]

The world keeps hearing and learning more and more of the Brilacidin story.
All of these new research and citations are published in the last 60 days.
I am happy to own so much good science for such a small price.
Now who will supply the money for the next big Brilacidin trial?

"Innovation Pharmaceuticals is evaluating Brilacidin which is a defense mimetic drug which has a potential in treating the coronavirus. Brilacidin has surprisingly shown many properties in several trials like antibacterial, anti-inflammatory and immune modulatory properties and now the company is aiming for exploring research collaboration and also to seek grant for manufacturing the drug [89]."
https://link.springer.com/article/10.1007/s12010-023-04439-4

"Peptides that possess the potential to inhibit viruses are considered antiviral peptides (AVPs) [8]. Compared with traditional small molecule drugs, AVPs are highly specific and effective, with fewer side effects and host toxicity and show great potential as antiviral drugs [16,17,18,19]. Numerous studies have indicated that AVPs exhibit excellent antiviral activities. Meanwhile, several peptidomimetics, peptide-like small molecules, and amino-acid-like derivatives are currently under investigation in clinical trials for treating various viral infections [26]. Brilacidin is a mimetic of defensin being tested under phase II clinical trials for treating COVID-19 (NCT04784897) [27]."
https://www.mdpi.com/1999-4915/15/4/820

"Moreover, new molecules, such as brilacidin, are promising in treated COVID-19"
https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.28660

"Other AMPs were also reported as potential alternative to control viral infections (Boas et al. 2019). For example, brilacidin, a synthetic peptide effectively inhibited SARS-CoV-2 in human lung cell line and monkey cell line independently and in combination with remdesivir (Bakovic et al. 2021)."
https://academic.oup.com/jambio/article/134/3/lxad054/7076875

"Biomimetic or de novo designed AMPs have become popular over the past two decades. De novo-generated peptide sequences have been adopted by numerous research teams to increase their activity, stability and reduce toxicity.Citation46 They mimic the structure, function and mode of action of native AMPs while being resistant to enzymatic degradation and exhibiting better pharmacological properties. Several of these substances have shown promise in clinical trials, such as the defensin-mimetic brilacidin."
https://www.tandfonline.com/doi/full/10.2147/IDR.S396566

"Host defense peptides (HDPs) are typically 12- 50 aa length expressed in neutrophils and mucosa, and serve as the first line of defense against foreign pathogens. Brilacidin, a synthetic HDP, demonstrates broad-spectrum antiviral against HCoV-OC43, -229E, -NL63, and SARS-CoV-2 but not influenza or enterovirus (Hu et al., 2022) through blocking virus attachment and early entry targeting heparan sulfate proteoglycans (HSPGs)."
https://www.sciencedirect.com/science/article/pii/S0168170223000400

"Table 6.
Top Hits Obtained After Virtual Screening Against a Conserved, Mutationally Impermeable, and Functionally Important Site in the DENV2 NS1 Protein.
Title State Function
Brilacidin Investigational Brilacidin is under investigation for the supportive care of Mucositis, Stomatitis, Mouth Diseases, and Head and Neck Neoplasms."
https://academic.oup.com/mbe/article/40/3/msad033/7043264

"Small Molecular Mimetics of Antimicrobial Peptides as a Promising Therapy to Combat Bacterial Resistance
as exemplified by a few synthetic membrane-active small molecular candidates in clinical trials such as brilacidin"
https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.2c00757

"Antimicrobial peptides (AMPs) have gained attention as potential alternatives to traditional antibiotics owing to their broad antimicrobial activity, high specificity, and ability to modulate host immunity.[4] Currently, AMPs have been explored as an alternative to antibiotic therapy for treating bacterial infections. This alternative therapy is superior in the treatment of bacterial infections (Table 1).
Table 1. AMPs in clinical trials to treat bacterial infections
PMX 30?063 (brilacidin) Staphylococcusspp Acute bacterial skin infections caused by Staphylococcusspp Phase II"
https://onlinelibrary.wiley.com/doi/full/10.1002/advs.202206602